Januvia - is a drug for adult patients with type 2 diabetes mellitus, in order to control the glycemic level under conditions of monotherapy as part of combined treatment regimens. The drug is prescribed to patients with ineffectiveness of diet therapy in combination with optimal physical activity, with the impossible use of metformin because of its intolerance.
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Yanuvia belongs to the group of incretins. It is a highly selective inhibitor of DPP-4, the medicine has been widely used in the treatment of type 2 diabetes.
The drug is prescribed to patients with ineffectiveness of diet therapy in combination with optimal physical activity.
Januvia is indicated as one of the components of combined therapy with metformin, sulfonylureas or PPAR-γ activator when there is no proper effect on glycemic control while dieting and moderate motor activity.
In the triple scheme of therapy, Yanuvia is used in combination with sulfonylurea/metformin or metformin/agonist PPAR-γ, when the clinical effect of the double scheme is not enough.
Januvia can be used against the background of insulin therapy with insufficient effectiveness of such therapy.
The daily amount of Yanuvia - 100 mg is taken once per os, regardless of food, in combination with other hypoglycemic agents or under conditions of monotherapy.
Yanuvia is not used in cases of excessive sensitivity to its constituents.
The medicine is prohibited for use in children and pregnant women, during lactation.
Insulin-dependent type of diabetes and ketoacidosis are direct contraindications to the use of Yanuvia.
In the area of the respiratorytract in monotherapy Janow most common adverse reactions were infections of the upper parts of it, nasopharyngitis. A combined treatment with Yanuvia with insulin was often accompanied by a flu.
Allergic reactions were noted with almost the same frequency in patients who took Yanugia, with monotherapy or as part of a two-three-component scheme.
Hypoglycemic conditions were most prevalent among patients who took Yanuvia with sulfonylureas - up to 14%, taking it against insulin therapy led to hypoglycemic conditions with a frequency of 9%.
In the central nervous system, the most common adverse reactions were dizziness, cranialgia, and excessive drowsiness.
From the gastrointestinal tract, when Yanuvia was admitted, there was dyspeptic syndrome, flatulence, stool disorders, discomfort in the upper abdominal cavity.
With the combination of Yanuvia with PPAR agonists, peripheral edema was often noted in patients.